Literature DB >> 10433219

erbB-2 overexpression in human mammary epithelial cells confers growth factor independence.

K M Ignatoski1, A J Lapointe, E H Radany, S P Ethier.   

Abstract

Previously, we demonstrated that human breast cancer cells with progressively elevated levels of constitutively tyrosine phosphorylated erbB-2 are independent of growth factors required by normal human mammary epithelial (HME) cells for proliferation in serum-free medium. To determine whether erbB-2 overexpression alone is sufficient to confer the growth factor-independence phenotype in HME cells, the spontaneously immortalized MCF-10A cell line and the HPV-16-immortalized H16N2 cell line were infected with the bicistronic retroviral vector pTPerbB-2 and tested for their ability to grow in the absence of specific factors. Selection of infected cells in G418-containing medium resulted in moderate levels of erbB-2 overexpression in approximately 40% of cells. The subpopulation of erbB-2 overexpressing cells could be selected for by culturing the cells in medium devoid of insulin. When MCF-10A or H16N2 cells were infected with pTPerbB-2 and directly selected in growth factor-deficient medium over long periods of time, populations of both cell lines emerged that expressed levels of erbB-2 protein equivalent to levels expressed by breast cancer cells with an erbB-2 gene amplification. Furthermore, overexpressed p185(erbB-2) was constitutively tyrosine phosphorylated in these cells. The levels of tyrosine phosphorylated p185(erbB-2) differed in the two recipient lines, with H16N2-erbB-2 cells having higher levels of activated receptor than MCF-10AerbB-2 cells. Furthermore, only the H16N2-erbB-2 cells were independent of both insulin and epidermal growth factor for growth in serum-free medium. Overexpression of erbB-2 also resulted in progressively increasing levels of tyrosine-phorphorylated erbB-3, without any significant changes in p180(erbB-3) levels. These studies demonstrate a direct relationship between the level of expression and activation of p185(erbB-2) and the requirements of HME cells for insulin-like and epidermal growth factor-like growth factors. The results also suggest that genetic alterations present in breast cancer cells, or mediated by HPV-16-induced alterations in pRb and p53, can influence the expression level and activation status of erbB-2 as well as erbB-3 and, in turn, their degree of growth factor independence.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10433219     DOI: 10.1210/endo.140.8.6939

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  24 in total

1.  A bcl-xS adenovirus selectively induces apoptosis in transformed cells compared to normal mammary cells.

Authors:  V N Sumantran; D S Lee; K M Woods Ignatoski; S P Ethier; M S Wicha
Journal:  Neoplasia       Date:  2000 May-Jun       Impact factor: 5.715

2.  The inhibitory effect of ErbB2 on epidermal growth factor-induced formation of clathrin-coated pits correlates with retention of epidermal growth factor receptor-ErbB2 oligomeric complexes at the plasma membrane.

Authors:  Camilla Haslekås; Kamilla Breen; Ketil W Pedersen; Lene E Johannessen; Espen Stang; Inger Helene Madshus
Journal:  Mol Biol Cell       Date:  2005-10-05       Impact factor: 4.138

3.  Cooperative interactions of HER-2 and HPV-16 oncoproteins in the malignant transformation of human mammary epithelial cells.

Authors:  Kathleen M Woods Ignatoski; Michele L Dziubinski; Cheryl Ammerman; Stephen P Ethier
Journal:  Neoplasia       Date:  2005-08       Impact factor: 5.715

4.  Insulin-like growth factor-1 receptor (IGF-1R) expression does not predict for resistance to trastuzumab-based treatment in patients with Her-2/neu overexpressing metastatic breast cancer.

Authors:  Wolfgang J Köstler; Gernot Hudelist; Werner Rabitsch; Klaus Czerwenka; Ruth Müller; Christian F Singer; Christoph C Zielinski
Journal:  J Cancer Res Clin Oncol       Date:  2005-09-24       Impact factor: 4.553

5.  Somatic loss of PIK3R1 may sensitize breast cancer to inhibitors of the MAPK pathway.

Authors:  Sanja B Turturro; Matthew S Najor; Timothy Yung; Liam Portt; Christopher S Malarkey; Abde M Abukhdeir; Melody A Cobleigh
Journal:  Breast Cancer Res Treat       Date:  2019-06-17       Impact factor: 4.872

6.  EGFR ligand switch in late stage prostate cancer contributes to changes in cell signaling and bone remodeling.

Authors:  Alyse M DeHaan; Natalie M Wolters; Evan T Keller; Kathleen M Woods Ignatoski
Journal:  Prostate       Date:  2009-04-01       Impact factor: 4.104

7.  Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia.

Authors:  Michael H Tomasson; Zhifu Xiang; Richard Walgren; Yu Zhao; Yumi Kasai; Tracie Miner; Rhonda E Ries; Olga Lubman; Daved H Fremont; Michael D McLellan; Jacqueline E Payton; Peter Westervelt; John F DiPersio; Daniel C Link; Matthew J Walter; Timothy A Graubert; Mark Watson; Jack Baty; Sharon Heath; William D Shannon; Rakesh Nagarajan; Clara D Bloomfield; Elaine R Mardis; Richard K Wilson; Timothy J Ley
Journal:  Blood       Date:  2008-02-12       Impact factor: 22.113

8.  HER2-mediated effects on EGFR endosomal sorting: analysis of biophysical mechanisms.

Authors:  Bart S Hendriks; H Steven Wiley; Douglas Lauffenburger
Journal:  Biophys J       Date:  2003-10       Impact factor: 4.033

9.  EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells.

Authors:  Celina G Kleer; Qi Cao; Sooryanarayana Varambally; Ronglai Shen; Ichiro Ota; Scott A Tomlins; Debashis Ghosh; Richard G A B Sewalt; Arie P Otte; Daniel F Hayes; Michael S Sabel; Donna Livant; Stephen J Weiss; Mark A Rubin; Arul M Chinnaiyan
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-19       Impact factor: 11.205

10.  Genomic amplification and oncogenic properties of the GASC1 histone demethylase gene in breast cancer.

Authors:  G Liu; A Bollig-Fischer; B Kreike; M J van de Vijver; J Abrams; S P Ethier; Z-Q Yang
Journal:  Oncogene       Date:  2009-09-28       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.